Home › Research › Topics › menopause-hrt-and-dementia
menopause-hrt-and-dementia
7 studies tagged menopause-hrt-and-dementia, dated 1998-03-01 to 2025-12-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis 2025-12-22
- Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study 2012-10-24
- Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study 2004-06-01
Studies
7 studies carry this tag.
Date range
1998 to 2025
Top journals
- JAMA 5
- Neurology 1
- The Lancet Healthy Longevity 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
No significant association was found between MHT use and risk of mild cognitive impairment or dementia.
-
Association of HT use and risk of AD may depend on timing of use.
-
For women aged 65 years or older, hormone therapy had an adverse effect on cognition, which was greater among women with lower cognitive function at initiation of treatment.
-
In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66).
-
The mean (SD) time between the date of randomization into WHI and the last Modified Mini-Mental State Examination (3MSE) for all WHIMS participants was 4.05 (1.19) years.
-
Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD.
-
Meta-analysis of these studies suggests a 29% decreased risk of developing dementia among estrogen users, but the findings of the studies are heterogeneous.